Novo-Nordisk A/S (NVO) Stock Price, News, Quotes-Moomoo

About Novo-Nordisk A/S Company

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsv?rd, Denmark.

Revenue Breakdown

Business Currency:DKK

2022/12/31

Stock NameRevenueRatio

Diabetes and Obesity care156.41B88.39%

Rare disease20.54B11.61%

Financial Indicators

EPS

According to the latest financial report of Novo-Nordisk A/S, the latest earnings per share (TTM) for the company is --. Investing in companies with strong earnings per share can potentially provide higher returns.

Quarterly

Loading...

News

Comments

Silverbat

11/29 02:48

Waiting dips

$Novo-Nordisk A/S(NVO.US)$

Shaaaw

11/28 17:22

Eli Lilly's $Eli Lilly and Co(LLY.US)$ Mounjaro is reportedly more effective for weight loss than Novo Nordisk's $Novo-Nordisk A/S(NVO.US)$ Ozempic in overweight or obese adults, according to a large analysis of real-world data - CNBC

2

JulianMackie

11/28 15:26

Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says

The blockbuster diabetes drug Mounjaro is more effective for weight loss than another highly popular diabetes treatment, Ozempic, in overweight or obese adults, according to a large analysis of real-world data published Monday.
Patients taking Eli Lilly’s Mounjaro were significantly more likely to lose 5%, 10% and 15% of their body weight overall and saw larger reductions in body weight ...

2